CEO Christian Mazzi said the minimally invasive surgical technique could provide better outcomes for patients than transcatheter aortic valve replacement.
Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported Q2 CY2025 results topping the market’s revenue expectations , with sales up 21.4% year on year to $2.44 billion. Its non-GAAP profit of $2.19 per share was 14.3% above analysts’ consensus estimates.
The orthopedics firm is looking to round out its robotics offerings with the planned $177 million acquisition. Some analysts questioned the value of a fully autonomous robot.
A surgical robot has successfully performed a key phase of a gallbladder removal with no human intervention, marking a critical leap toward fully autonomous operations.
Developed by Johns Hopkins University researchers and funded by the U.S. government, the system demonstrated expert-level performance while adapting to unpredictable conditions and responding to voice commands like a human trainee.
Intuitive Surgical on Wednesday said its da Vinci 5 robot received CE mark approval for adult and pediatric use in Europe across multiple minimally invasive procedures, including urologic, gynecologic and general laparoscopic.
Intuitive announced Thursday that it received FDA clearance for a new indication for its da Vinci single port (SP) surgical robot.
Intuitive said Thursday the Food and Drug Administration has cleared a stapler for use with its single-port robotic surgery system.
The device, which Intuitive said is the first stapler designed for single-port robotic surgery, shares features found in the company’s multi-port products to reduce the risk of tissue damage.
Intuitive Surgical will face competition this year from Medtronic and smaller companies like CMR Surgical and Moon Surgical coming to the U.S. market with robotic surgery systems.